Animal and cell models for type II diabetes and their use
US7098375B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 6, 2001 |
| Grant date | Aug 29, 2006 |
| Priority date | — |
| Expiry date | May 14, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2517/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A transgenic diabetes type II model laboratory animal is disclosed which comprises β-cells expressing a dominant negative form (dnFGFR1c) of FGFR1c. Also disclosed is the use of the Ipf1/pdx1 promoter for controlling expression of FGFR1c; β-cells in which the expression of PC1/3 is down-regulated or absent or which are competent to express a dominant negative form (dnFGFR1c) of FGFR1c; mature β-cells incompetent to express Glut2 or in which the processing of proinsulin is substantially impaired; a method of preventing or treating type II diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.